Abstract
As the first step of a research program aimed at developing a bispecific monoclonal antibody system for the delivery of boron-rich molecules to tumor cells for boron neutron capture therapy, monoclonal antibodies (mAbs) were produced against an anionic nido-carborane derivative, 4-[7,8-dicarbadodecahydroundecaborat(-1)-7-yl]butanoic acid. Two IgG subclass mAbs, designated HAW101 and HAW102, were identified that specifically bound the anionic nido-carborane hapten, as well as a variety of other anionic nido-carborane cage derivatives. By using surface plasmon resonance technology, the affinity constants of HAW101 and HAW102 were determined to be 1.9 x 10(9) and 6.8 x 10(8) M-1, respectively. A diverse array of 7-substituted and 7,8-disubstituted anionic nido-carborane derivatives reacted with the mAb HAW101 in competition ELISA, whereas anionic closo-polyhedral boranes showed negligible binding, suggesting a role for the open nido-carborane cage structure. These results suggest that mAbs such as HAW101, which bind anionic nido-carboranes, are useful in the development of bispecific mAbs for specific targeting and enhanced boron delivery to tumor sites.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barth R. F., Adams D. M., Soloway A. H., Alam F., Darby M. V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem. 1994 Jan-Feb;5(1):58–66. doi: 10.1021/bc00025a008. [DOI] [PubMed] [Google Scholar]
- Barth R. F., Soloway A. H., Fairchild R. G. Boron neutron capture therapy of cancer. Cancer Res. 1990 Feb 15;50(4):1061–1070. [PubMed] [Google Scholar]
- Chen C. J., Kane R. R., Primus F. J., Szalai G., Hawthorne M. F., Shively J. E. Synthesis and characterization of oligomeric nido-carboranyl phosphate diester conjugates to antibody and antibody fragments for potential use in boron neutron capture therapy of solid tumors. Bioconjug Chem. 1994 Nov-Dec;5(6):557–564. doi: 10.1021/bc00030a011. [DOI] [PubMed] [Google Scholar]
- Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods. 1991 Dec 15;145(1-2):229–240. doi: 10.1016/0022-1759(91)90331-9. [DOI] [PubMed] [Google Scholar]
- Neumaier M., Shively L., Chen F. S., Gaida F. J., Ilgen C., Paxton R. J., Shively J. E., Riggs A. D. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res. 1990 Apr 1;50(7):2128–2134. [PubMed] [Google Scholar]
- Nolan O., O'Kennedy R. Bifunctional antibodies: concept, production and applications. Biochim Biophys Acta. 1990 Aug 1;1040(1):1–11. doi: 10.1016/0167-4838(90)90139-7. [DOI] [PubMed] [Google Scholar]
- Paxton R. J., Beatty B. G., Varadarajan A., Hawthorne M. F. Carboranyl peptide-antibody conjugates for neutron-capture therapy: preparation, characterization, and in vivo evaluation. Bioconjug Chem. 1992 May-Jun;3(3):241–247. doi: 10.1021/bc00015a007. [DOI] [PubMed] [Google Scholar]
- Rath S., Stanley C. M., Steward M. W. An inhibition enzyme immunoassay for estimating relative antibody affinity and affinity heterogeneity. J Immunol Methods. 1988 Feb 10;106(2):245–249. doi: 10.1016/0022-1759(88)90204-9. [DOI] [PubMed] [Google Scholar]